Presenting recurring profitability through core operating profit
First written in FY2026-H1. 2 of 4 entries say "Advanced", first in 2026-05-14. Latest entry: 2026-08-06.
The whole theme swung hardest in 2021: 1 of 12 companies on the "Worse" side.
2 other companies' latest entry also says "Cited as achieved".
- 2026-08-06Cited as achievedFinancial results
「For the cumulative first quarter of the fiscal year under review, net sales were ¥154,600 million, up 104.3% year on year, and operating income was ¥643 million, or 79.8% of the previous year's level. Core operating income, before deducting research and development expenses in the new pharmaceutical business, an unapproved-drug introduction support business, was ¥1,041 million, or 93.6% of the previous year's level.」
Discloses core operating income before deducting research and development expenses as a profitability metric based on first-quarter results. - FY2026AdvancedAnnual report
「From the current fiscal year, in addition to the conventional “operating profit,” the company will calculate “core operating profit” before deducting research and development expenses and use it as an indicator of recurring business profitability.」
The company continues to disclose core operating profit as a full-year profitability indicator, calculating it at ¥5,307 million for the current fiscal year. - 2026-05-14AdvancedFinancial results
「For the consolidated fiscal year under review, net sales were ¥610,497 million, up 101.7% year on year, and operating income was ¥4,027 million, or 70.6% of the previous year's level. Core operating income, before deducting research and development expenses in the new pharmaceutical business, an unapproved-drug introduction support business, was ¥5,307 million, or 93.0% of operating income in the previous fiscal year.」
Discloses full-year core operating income before deducting research and development expenses of ¥5,307 million, applying the new profitability metric to actual results. - FY2026-H1First statedAnnual report
「※From the current fiscal year, in addition to the conventional “operating profit,” the company will calculate “core operating profit” before deducting research and development expenses and use it as an indicator of recurring business profitability.」
To distinguish the impact of research and development expenses in the pharmaceutical business, the company calculates and discloses core operating profit before the deduction of research and development expenses as a new profitability indicator in addition to operating profit.